As CBZ and PHT are currently approved for use in humans, the documented inhibitory effect of these antiepileptic agents on pathological GFAP cellular expression and folding may indicate their potential therapeutic role as disease-modifying agents in the clinical management of AxD, particularly in AxD patients with focal epilepsy with and without secondary generalization. This evidence concerns the gene GFAP and focal epilepsy.